PL2702155T3 - Związki mikroRNA i sposoby modulowania aktywności miR-21 - Google Patents
Związki mikroRNA i sposoby modulowania aktywności miR-21Info
- Publication number
- PL2702155T3 PL2702155T3 PL12718549T PL12718549T PL2702155T3 PL 2702155 T3 PL2702155 T3 PL 2702155T3 PL 12718549 T PL12718549 T PL 12718549T PL 12718549 T PL12718549 T PL 12718549T PL 2702155 T3 PL2702155 T3 PL 2702155T3
- Authority
- PL
- Poland
- Prior art keywords
- activity
- methods
- modulating mir
- microrna compounds
- microrna
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 108091062762 miR-21 stem-loop Proteins 0.000 title 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 title 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 title 1
- 108091070501 miRNA Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478767P | 2011-04-25 | 2011-04-25 | |
| US201161565779P | 2011-12-01 | 2011-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2702155T3 true PL2702155T3 (pl) | 2017-09-29 |
Family
ID=46025979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12718549T PL2702155T3 (pl) | 2011-04-25 | 2012-04-25 | Związki mikroRNA i sposoby modulowania aktywności miR-21 |
| PL17153724T PL3211082T3 (pl) | 2011-04-25 | 2012-04-25 | Związki mikroRNA i sposoby modulowania aktywności miR-21 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17153724T PL3211082T3 (pl) | 2011-04-25 | 2012-04-25 | Związki mikroRNA i sposoby modulowania aktywności miR-21 |
Country Status (30)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1838852A2 (en) | 2004-11-12 | 2007-10-03 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| PL2702155T3 (pl) | 2011-04-25 | 2017-09-29 | Regulus Therapeutics Inc. | Związki mikroRNA i sposoby modulowania aktywności miR-21 |
| EP2836219A1 (en) * | 2012-04-10 | 2015-02-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of nonalcoholic steatohepatitis |
| IN2014DN09134A (cg-RX-API-DMAC7.html) * | 2012-04-25 | 2015-05-22 | Regulus Therapeutics Inc | |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| WO2014076196A1 (en) | 2012-11-15 | 2014-05-22 | Santaris Pharma A/S | Anti apob antisense conjugate compounds |
| CN105378080A (zh) * | 2013-05-01 | 2016-03-02 | 莱古路斯治疗法股份有限公司 | 用于调节mir-122的微小rna化合物和方法 |
| WO2015061536A1 (en) * | 2013-10-25 | 2015-04-30 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| KR101625755B1 (ko) | 2013-11-18 | 2016-05-30 | 울산대학교 산학협력단 | ｍｉＲＮＡ 스폰지 및 이의 용도 |
| US10358643B2 (en) * | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| CN105734127A (zh) * | 2016-02-29 | 2016-07-06 | 上海中医药大学 | miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途 |
| EP3449001B1 (en) * | 2016-04-29 | 2021-12-08 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| AU2018335876B2 (en) | 2017-09-22 | 2024-03-14 | University Of Washington | In situ combinatorial labeling of cellular molecules |
| CN108148911B (zh) * | 2018-03-02 | 2019-11-05 | 广州医科大学附属第二医院 | miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用 |
| WO2019217369A1 (en) | 2018-05-08 | 2019-11-14 | Regulus Therapeutics Inc. | Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect |
| CN110747266A (zh) * | 2018-07-23 | 2020-02-04 | 深圳先进技术研究院 | miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用 |
| CN109880907A (zh) * | 2019-03-26 | 2019-06-14 | 中国人民解放军第八一医院 | 一种肝癌细胞侵袭转移的分子机制研究方法 |
| US11965162B2 (en) | 2020-04-16 | 2024-04-23 | The Johns Hopkins University | MicroRNA and inhibitors thereof and methods of treatment |
| WO2022165092A1 (en) * | 2021-01-29 | 2022-08-04 | Angion Biomedica Corp. | Methods for treatment of fibrotic diseases |
| WO2025110217A1 (ja) * | 2023-11-22 | 2025-05-30 | 国立大学法人東海国立大学機構 | 嚢胞性腎疾患の予防及び／又は治療剤 |
| CN120505413A (zh) * | 2025-07-15 | 2025-08-19 | 湖南工程学院 | 一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200003432T2 (tr) | 1998-05-22 | 2001-03-21 | Boys Town National Research Hospital | Alfa1beta1 birleştirici alıcı önleyicilerinin kullanılması ve böbrek hastalığının tedavisinde TGF-beta1 önleyicileri. |
| US20060008817A1 (en) * | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
| CA2462144C (en) | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Micro-rna molecules |
| AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| US7582744B2 (en) | 2004-08-10 | 2009-09-01 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| WO2006029173A2 (en) | 2004-09-08 | 2006-03-16 | Boys Town National Research Hospital | Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12 |
| EP1838852A2 (en) | 2004-11-12 | 2007-10-03 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| WO2006069584A2 (en) | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
| US6995235B1 (en) | 2005-05-02 | 2006-02-07 | Univation Technologies, Llc | Methods of producing polyolefins and films therefrom |
| DK1931780T3 (en) * | 2005-08-29 | 2016-01-25 | Regulus Therapeutics Inc | Antisense-forbindelser med forøget anti-microrna-aktivitet |
| JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| CN102908630B (zh) | 2006-01-27 | 2014-11-19 | Isis制药公司 | 6-修饰的双环核酸类似物 |
| EP2007889A2 (en) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
| NZ571569A (en) * | 2006-04-03 | 2011-09-30 | Santaris Pharma As | Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| JP2010505427A (ja) | 2006-10-09 | 2010-02-25 | ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ | 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ） |
| AU2007333107A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
| WO2008086807A2 (en) | 2007-01-19 | 2008-07-24 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| US20100261175A1 (en) | 2007-06-15 | 2010-10-14 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
| ES2376507T5 (es) | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos 6-disustituidos |
| MX2010003299A (es) * | 2007-10-04 | 2010-04-14 | Santaris Pharma As | Oligonucleotidos muy cortos (micromirs). |
| JP5535076B2 (ja) * | 2007-10-29 | 2014-07-02 | レグルス・セラピューティクス・インコーポレイテッド | 肝臓癌を治療するための標的化ミクロｒｎａ |
| US20110257244A1 (en) | 2008-01-18 | 2011-10-20 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
| NZ587178A (en) | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| AU2010218147A1 (en) * | 2009-02-26 | 2011-10-20 | The Government Of The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services | MicroRNAs in never-smokers and related materials and methods |
| AU2010258875A1 (en) | 2009-06-08 | 2012-01-19 | Miragen Therapeutics | Chemical modification motifs for miRNA inhibitors and mimetics |
| WO2011126842A2 (en) | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
| PL2702155T3 (pl) | 2011-04-25 | 2017-09-29 | Regulus Therapeutics Inc. | Związki mikroRNA i sposoby modulowania aktywności miR-21 |
| WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
| IN2014DN09134A (cg-RX-API-DMAC7.html) | 2012-04-25 | 2015-05-22 | Regulus Therapeutics Inc | |
| CN107236735B (zh) | 2012-06-21 | 2019-11-08 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| US9725721B2 (en) | 2012-09-26 | 2017-08-08 | Mirrx Therapeutics | Oligomers with improved off-target profile |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
-
2012
- 2012-04-25 PL PL12718549T patent/PL2702155T3/pl unknown
- 2012-04-25 CA CA3165397A patent/CA3165397A1/en active Pending
- 2012-04-25 ES ES17153724T patent/ES2868950T3/es active Active
- 2012-04-25 RS RS20210552A patent/RS61775B1/sr unknown
- 2012-04-25 AU AU2012249851A patent/AU2012249851B2/en active Active
- 2012-04-25 KR KR1020137031227A patent/KR102055172B1/ko active Active
- 2012-04-25 BR BR112013027187A patent/BR112013027187A2/pt not_active Application Discontinuation
- 2012-04-25 MX MX2019003090A patent/MX393138B/es unknown
- 2012-04-25 US US13/455,337 patent/US20120270928A1/en active Pending
- 2012-04-25 HR HRP20170557TT patent/HRP20170557T2/hr unknown
- 2012-04-25 NZ NZ717921A patent/NZ717921A/en unknown
- 2012-04-25 US US14/111,976 patent/US9181547B2/en active Active
- 2012-04-25 EP EP12718549.4A patent/EP2702155B9/en active Active
- 2012-04-25 MX MX2013012452A patent/MX2013012452A/es unknown
- 2012-04-25 DK DK12718549.4T patent/DK2702155T3/en active
- 2012-04-25 CN CN201280031285.4A patent/CN103620035B/zh active Active
- 2012-04-25 PH PH1/2013/502199A patent/PH12013502199A1/en unknown
- 2012-04-25 SI SI201231913T patent/SI3211082T1/sl unknown
- 2012-04-25 CA CA2833615A patent/CA2833615C/en active Active
- 2012-04-25 KR KR1020197015054A patent/KR20190063482A/ko not_active Ceased
- 2012-04-25 PT PT171537244T patent/PT3211082T/pt unknown
- 2012-04-25 WO PCT/US2012/034880 patent/WO2012148952A1/en not_active Ceased
- 2012-04-25 ES ES12718549.4T patent/ES2621863T3/es active Active
- 2012-04-25 MY MYPI2017000706A patent/MY187685A/en unknown
- 2012-04-25 TW TW106131684A patent/TWI698445B/zh active
- 2012-04-25 PL PL17153724T patent/PL3211082T3/pl unknown
- 2012-04-25 EP EP21157334.0A patent/EP3933040A1/en not_active Withdrawn
- 2012-04-25 DK DK17153724.4T patent/DK3211082T3/da active
- 2012-04-25 JP JP2014508494A patent/JP6320292B2/ja active Active
- 2012-04-25 PT PT127185494T patent/PT2702155T/pt unknown
- 2012-04-25 LT LTEP17153724.4T patent/LT3211082T/lt unknown
- 2012-04-25 EP EP17153724.4A patent/EP3211082B1/en active Active
- 2012-04-25 TW TW101114636A patent/TWI607016B/zh active
- 2012-04-25 SG SG2013079454A patent/SG194636A1/en unknown
- 2012-04-25 HU HUE12718549A patent/HUE031595T2/en unknown
- 2012-04-25 CN CN202110384864.8A patent/CN113151272A/zh active Pending
- 2012-04-25 EA EA201391492A patent/EA025894B1/ru not_active IP Right Cessation
- 2012-04-25 SI SI201230924A patent/SI2702155T1/sl unknown
- 2012-04-25 MY MYPI2013003885A patent/MY175336A/en unknown
- 2012-04-25 LT LTEP12718549.4T patent/LT2702155T/lt unknown
- 2012-04-25 UA UAA201312414A patent/UA115652C2/uk unknown
- 2012-04-25 HU HUE17153724A patent/HUE054129T2/hu unknown
- 2012-04-25 CN CN202110383567.1A patent/CN113249381A/zh active Pending
-
2013
- 2013-10-23 IL IL229032A patent/IL229032B/en active IP Right Grant
- 2013-10-23 MX MX2019003089A patent/MX2019003089A/es unknown
- 2013-10-23 MX MX2022006595A patent/MX2022006595A/es unknown
- 2013-10-23 MX MX2022000212A patent/MX2022000212A/es unknown
- 2013-10-25 CL CL2013003105A patent/CL2013003105A1/es unknown
- 2013-10-30 CO CO13257480A patent/CO6821889A2/es unknown
-
2014
- 2014-07-28 US US14/444,406 patent/US8912161B2/en active Active
-
2015
- 2015-10-14 US US14/883,055 patent/US9790496B2/en active Active
-
2017
- 2017-04-25 CY CY20171100460T patent/CY1120304T1/el unknown
- 2017-08-29 AU AU2017219156A patent/AU2017219156B2/en active Active
- 2017-09-14 US US15/704,749 patent/US20180155719A1/en not_active Abandoned
-
2018
- 2018-04-02 JP JP2018070694A patent/JP2018121646A/ja active Pending
-
2019
- 2019-05-08 IL IL266529A patent/IL266529A/en unknown
-
2020
- 2020-01-24 US US16/751,402 patent/US20200291400A1/en not_active Abandoned
- 2020-02-26 AU AU2020201403A patent/AU2020201403A1/en not_active Abandoned
- 2020-03-18 IL IL273381A patent/IL273381A/en unknown
-
2021
- 2021-04-19 HR HRP20210616TT patent/HRP20210616T1/hr unknown
- 2021-08-18 US US17/405,482 patent/US12331294B2/en active Active
-
2022
- 2022-05-06 AU AU2022203067A patent/AU2022203067A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273381A (en) | MicroRNA compounds and methods to modulate mir-21 activity | |
| ZA201407228B (en) | Microrna compounds and methods for modulating mir-21 activity | |
| GB2528399B (en) | Catalyst and method for its preparation | |
| PT3636274T (pt) | Composições para modular a atividade das citocinas gama-c | |
| IL228546A0 (en) | fermentation process | |
| GB201112231D0 (en) | Micro-organism | |
| IL229446A0 (en) | Rolled collagen carrier | |
| SG11201403280PA (en) | Bioreactor | |
| EP2864469A4 (en) | BIOREACTOR CARTRIDGE AND SYSTEM | |
| IL228700A0 (en) | A method for modulating cytokine activity | |
| GB201108165D0 (en) | Bioreactor chamber and method | |
| GB201109849D0 (en) | Modulation | |
| AU2011011V (en) | FFV1 Ficus obliqua | |
| GB201111898D0 (en) | Bioreactor chamber and method | |
| GB201122254D0 (en) | Bioreactor chamber and method | |
| GB201105579D0 (en) | Osteoclast activity | |
| GB201105580D0 (en) | Osteoclast activity | |
| GB201105578D0 (en) | Osteoclast activity |